Johannes T Reckweg
Biographic Data
| ID | 7378262 |
|---|---|
| NAME | Johannes T Reckweg |
| GIVEN NAMES | Johannes T |
| FAMILY NAME | Reckweg |
| SIGNATURE | RECKWEG J T |
| AFFILIATIONS | Maastricht University |
| ORCID | 0000-0001-7916-6334 |
| VERIFIED | Yes |
| TOTAL WORKS | 1 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 1 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2023 |
| LATEST PUBLICATION YEAR | 2023 |
| H-INDEX | 0 |
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
Administration of GH001 to a cohort of 16 patients with TRD was well tolerated and provided potent and ultra-rapid antidepressant effects. Individualized dosing with up to three doses of GH001 on a single day was superior to single dose administration. Clinical Trial registration : Clinicaltrials.gov Identifier NCT04698603
No prominent works on this page.
A phase 1/2 trial to assess safety and efficacy of a vaporized 5-methoxy-N,N-dimethyltryptamine formulation (GH001) in patients with treatment-resistant depression
Administration of GH001 to a cohort of 16 patients with TRD was well tolerated and provided potent and ultra-rapid antidepressant effects. Individualized dosing with up to three doses of GH001 on a single day was superior to single dose administration. Clinical Trial registration : Clinicaltrials.gov Identifier NCT04698603
Adverse effect (1 work) · Antidepressant (1 work) · Chemical synthesis and alkaloids (1 work) · Clinical endpoint (1 work) · Clinical trial (1 work) · Depression (economics (1 work) · Dosing (1 work) · Internal Medicine (1 work) · Medicine (1 work) · Neurotransmitter Receptor Influence on Behavior (1 work)